Osimertinib after Chemoradiotherapy in Stage III <i>EGFR</i> -Mutated NSCLCShun Lu, Suresh S. Ramalingam, Takako Inoue et al.|New England Journal of Medicine|2024Cited by 291
Consensus on the diagnosis and treatment of unresectable stage III driver gene-positive non-small cell lung cancerXiangjiao Meng, Jinming Yu, Nan Bi et al.|Cancer Letters|2025Cited by 2
PPD01.02 Repotrectinib in Patients With ROS1 Fusion-Positive (ROS1+) NSCLC: Update From the Pivotal Phase 1/2 TRIDENT-1 TrialAlexander Drilon, Byoung Chul Cho, D. Ross Camidge et al.|Journal of Thoracic Oncology|2024Cited by 0